Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals (stock code: 603087.SH) was founded in 1998 and is headquartered in Beijing. It specializes in the development, production, and commercialization of insulin analogs and medical devices, and developed the first Chinese domestic insulin analog. The company has more than 5,500 employees globally and an industrial park of about 200,000 square meters.

Gan & Lee Pharmaceuticals was founded in 1998 as Beijing Gan & Lee Biotechnology Co., Ltd. (later became Gan & Lee Pharmaceuticals) and completed the construction of the world's 3rd largest recombinant human insulin production base. In 2001, it successfully developed China's 1st fast-acting human insulin analog, Prandilin® (Lispro). In 2002, it developed China's 1st long-acting human insulin analog, Basalin® (Glargine), and China's 1st premixed human insulin analog, Prandilin® 25 (Lispro 25R). In 2005, the company was restructured and renamed to "Gan & Lee Pharmaceuticals"; it obtained patents for Molecular Chaperone Technology in China and a PCT patent in the US, and received production approval and GMP certificate for Basalin® from the NMPA (before CFDA). In 2007, Basalin® went on sale. In 2008, Basalin® entered the international market, including Egypt, Pakistan, Mexico, etc. In 2009, the company's sales revenue exceeded RMB100 million.

• 2026

  Multiple international approvals for insulin products; partnership with Menarini Group for Bofanglutide in Europe; entry into recombinant human albumin research.

• 2020

  Listed on the Shanghai Stock Exchange under stock code 603087.SH.

• 2009

  Company's sales revenue exceeded RMB 100 million.

• 2008

  Basalin entered the international market, including Egypt, Pakistan, Mexico, etc.

• 2007

  Basalin went on sale.

• 2005

  Company restructured and renamed to Gan & Lee Pharmaceuticals; obtained patents for Molecular Chaperone Technology in China and PCT patent in the US; received production approval and GMP certificate for Basalin from NMPA.

• 2002

  Successfully developed China's 1st long-acting human insulin analog – Basalin (Glargine) and China's 1st premixed human insulin analog – Prandilin 25 (Lispro 25R).

• 2001

  Successfully developed China's 1st fast-acting human insulin analog – Prandilin (Lispro).

• 1998

  Founded as Beijing Gan & Lee Biotechnology Co., Ltd.; completed construction of the world's 3rd largest recombinant human insulin production base.

A leading pharmaceutical company in China specializing in insulin analogs and medical devices, with a mission to provide scientific solutions to patients across the globe.

• Prandilin® (Lispro)

  China's 1st fast-acting human insulin analog, successfully developed in 2001.

• Basalin® (Glargine)

  China's 1st long-acting human insulin analog, successfully developed in 2002; went on sale in 2007; entered international markets in 2008.

• Prandilin® 25 (Lispro 25R)

  China's 1st premixed human insulin analog, successfully developed in 2002.

• 2013

  Source

Read more

• 2020-07-27

  Gan & Lee clarifies executives remain with the company[8]甘李药业澄清高管辞职后仍在公司任职finance.sina.com.cn

  Reported: 2020-07-27

  Gan & Lee issued a clarification saying that three executives who resigned from certain positions would remain employed by the company; Gan Zhongru would continue as chairman after resigning as general manager.

• 2020-07-20

  Gan & Lee executives resign from senior management roles[9]甘李药业多名高管辞去高级管理职务finance.sina.com.cn

  Reported: 2020-07-20

  Gan & Lee Pharmaceuticals announced that Gan Zhongru, Wang Damei, and Ning Junjun had resigned from their roles as general manager, deputy general manager, and finance head, respectively, for personal reasons. Their resignations took effect when submitted to the board; Gan Zhongru and Wang Damei retained other company roles.

1. 1Gan & Lee - Dedicated to Improving Human Healthganlee.com
2. 2History-Gan & Leeganlee.com
3. 3Overview-Gan & Leeganlee.com
4. 4Company News-Gan & Leeganlee.com
5. 5Gan & Lee Pharmaceuticals Co., Ltd. - Wikidatawikidata.org
6. 6被举报行贿医生8亿元、7名医药代表被批捕chinanews.com
7. 7被举报行贿医生8亿元、7名医药代表被批捕jjckb.cn
8. 8甘李药业澄清高管辞职后仍在公司任职finance.sina.com.cn
9. 9甘李药业多名高管辞去高级管理职务finance.sina.com.cn
10. 10甘李药业人事大变动 甘忠如等高管辞去部分职务推高管层年轻化战略finance.sina.com.cn